Seattle, Washington, United States, November 2025 – Dionysus Health, a pioneering precision diagnostics company transforming maternal mental health through epigenetics and artificial intelligence, has announced the appointment of Rashmi Raghavendra as its new Chief Executive Officer. The leadership transition marks a critical inflection point as the company advances from clinically validated science to commercial launch of its breakthrough maternal mental health diagnostic platform.
Rashmi Raghavendra is an internationally recognized leader in digital health, diagnostics, and healthcare AI, with over 20 years of experience building early-stage ventures into high-impact businesses. Her track record includes leadership roles at Apple, Samsung, Qualcomm, and Philips Healthcare, and she has successfully created over $500 million in healthcare revenue. As Founder and Managing Director of rcubed | ventures, she has also played a pivotal role in accelerating women’s health innovations, predictive diagnostics, and virtual care solutions.
Welcoming the appointment, Dr. Andrea Cubitt, Co-Founder and Board Director of Dionysus Health, stated:
“Rashmi’s appointment marks a transformative milestone for Dionysus Health. Her deep expertise in commercialization, healthcare AI, and diagnostics innovation will guide our next chapter as we bring our clinically validated science into real-world impact for mothers everywhere.”
Raghavendra steps into her new role as the company gears up for major milestones, including:
- First commercial pilots launching in December 2025 in Florida with leading OB-GYN groups
- FDA Breakthrough Device Designation expected in 2026
- Full FDA approval anticipated by 2027
The company’s flagship diagnostic test, which can identify a woman’s risk for postpartum depression as early as 24 weeks into pregnancy, has been clinically validated in over 600 participants, demonstrating up to 90% predictive accuracy. This innovation is supported by $14.5 million in non-dilutive funding from the National Institutes of Health (NIH) and the U.S. Department of Defense (DoD).
Expressing her vision, Rashmi Raghavendra said:
“Dionysus Health is redefining what’s possible in maternal mental health. By harnessing epigenetics and AI, our technology shifts care from reaction to prevention, empowering clinicians to identify risk for postpartum depression as early as 24 weeks into pregnancy. I’m honored to lead this mission and bring proactive care to women and families who’ve waited far too long. As both a mother and a healthcare executive, this work is deeply personal.”
Her appointment further reflects the company’s strategic intent to lead the paradigm shift in maternal care, leveraging cutting-edge science to address one of the most underdiagnosed and under-treated health conditions affecting women today.
About Dionysus Health
Dionysus Health is a precision diagnostics company leveraging AI and epigenetics to predict and prevent postpartum depression before it starts. Its proprietary blood test can detect biological changes as early as 24 weeks of pregnancy, enabling clinicians to identify risk well before symptoms arise. Validated in more than 600 participants and supported by $14.5 million in funding from the NIH and DoD, the test has shown up to 90% predictive accuracy. The company anticipates FDA Breakthrough Device designation in 2026 and full FDA approval by 2027, with its first commercial pilots launching in December 2025. Dionysus Health’s mission is to make predictive maternal mental health screening a standard of care, ultimately improving outcomes for mothers, families, and communities.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
